Immunotherapy plus chemo shows promise in aggressive breast cancer trial
NCT ID NCT07256964
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This Phase 2 trial tests whether adding the immunotherapy drug toripalimab to chemotherapy before surgery can improve outcomes for people with triple-negative breast cancer. About 216 participants will receive either toripalimab plus one of two chemotherapy regimens. The main goal is to see if the cancer completely disappears by the time of surgery.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- toripalimab (a PD-1 inhibitor) combined with chemotherapy drugs (albumin paclitaxel, carboplatin, epirubicin, cyclophosphamide)
- What this could lead to
- If successful, this could lead to a more effective pre-surgery treatment for triple-negative breast cancer, potentially improving survival and reducing recurrence.
- What could go wrong
- This is an early-phase (Phase 2) trial with only 216 participants, so results may not apply to all patients. The combination may cause significant side effects, and it is not yet known if it will outperform standard treatments.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TNBC - TRIPLE-NEGATIVE BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can Gene-Edited immune cells tame Hard-to-Treat cancers?
- Can a One-Time Anti-Inflammatory shot during surgery curb Triple-Negative breast Cancer's return?
- Triple-Drug cocktail aims to stall aggressive breast cancer
- Could a vaccine stop Triple-Negative breast cancer from coming back?
- Engineered immune cells take aim at Mesothelin-Positive tumors
- New imaging tracer could spot hidden cancers